

Assessment of omega-3 carboxylic acids in statin-treated patients with elevated triglycerides and low levels of high-density lipoprotein cholesterol: results of the STRENGTH trial

Clinical Cardiology

41, 1281-1288

DOI: 10.1002/clc.23055

Citation Report

#	ARTICLE	IF	CITATIONS
1	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal, 2018, 48, 1097.	0.7	15
2	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
3	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clinical Cardiology, 2018, 41, 1281-1288.	0.7	151
4	Translating plasma eicosapentaenoic acid concentrations into erythrocyte percentages of eicosapentaenoic acid plus docosahexaenoic acid during treatment with icosapent ethyl. Journal of Clinical Lipidology, 2019, 13, 771-777.	0.6	1
5	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	0.6	10
6	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019, 140, e673-e691.	1.6	282
7	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet, The, 2019, 394, 697-708.	6.3	67
8	A New Beginning for Triglyceride-Lowering Therapies. Circulation, 2019, 140, 167-169.	1.6	6
9	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clinical Cardiology, 2019, 42, 829-838.	0.7	13
10	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.4	1
11	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	1
12	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. Journal of the American College of Cardiology, 2019, 74, 1926-1942.	1.2	39
13	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of Clinical Lipidology, 2019, 13, 860-872.	0.6	79
14	Implications for REDUCE IT in clinical practice. Progress in Cardiovascular Diseases, 2019, 62, 395-400.	1.6	12
15	Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients, 2019, 11, 2599.	1.7	21
16	Omega-3 Polyunsaturated Fatty Acids and Stroke Burden. International Journal of Molecular Sciences, 2019, 20, 5549.	1.8	14
17	An update on pharmacotherapies in diabetic dyslipidemia. Progress in Cardiovascular Diseases, 2019, 62, 334-341.	1.6	24
18	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753

#	ARTICLE	IF	CITATIONS
19	Fish Oil and Cardiometabolic Diseases: Recent Updates and Controversies. <i>American Journal of Medicine</i> , 2019, 132, 1153-1159.	0.6	16
20	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. <i>Diabetes Care</i> , 2019, 42, 2307-2314.	4.3	43
21	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	2.0	124
22	Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 84.	2.7	36
23	Risk of Total Events With Icosapent Ethyl. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2803-2805.	1.2	8
24	The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. <i>Postgraduate Medicine</i> , 2019, 131, 268-277.	0.9	96
25	The time for lipoprotein(a) based intervention has arrived: where will the light shine?. <i>Journal of Thoracic Disease</i> , 2019, 11, S433-S436.	0.6	3
26	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-38.	2.2	31
27	What is new in lipid-lowering therapies in diabetes?. <i>Internal Medicine Journal</i> , 2019, 49, 1472-1480.	0.5	5
28	Triglycerides and cardiovascular risk: Apolipoprotein B holds the key. <i>Atherosclerosis</i> , 2019, 284, 221-222.	0.4	15
29	Trials in Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 960-967.	2.3	2
30	Current pharmacotherapies for atherosclerotic cardiovascular diseases. <i>Archives of Pharmacal Research</i> , 2019, 42, 206-223.	2.7	10
31	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. <i>European Heart Journal</i> , 2020, 41, 86-94.	1.0	71
32	Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial. <i>Future Cardiology</i> , 2019, 15, 391-394.	0.5	10
33	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1059-1079.	1.9	3
34	Dyslipidemia in nonalcoholic fatty liver disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 103-108.	1.2	33
35	Triglycerides and endothelial function: molecular biology to clinical perspective. <i>Current Opinion in Lipidology</i> , 2019, 30, 364-369.	1.2	16
36	Cardiovascular risk reduction with icosapent ethyl. <i>Current Opinion in Cardiology</i> , 2019, 34, 721-727.	0.8	23

#	ARTICLE	IF	CITATIONS
37	Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 366-371.	2.2	90
39	Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 23-32.	13.9	684
40	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019, 380, 11-22.	13.9	2,153
41	Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2019, 21, 1.	2.0	40
42	New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2019, 21, 2.	2.0	87
43	Recent advances in synthetic pharmacotherapies for dyslipidaemias. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1576-1596.	0.8	24
44	The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. <i>Angiology</i> , 2020, 71, 10-16.	0.8	21
45	Dyslipidemia Management in Adults With Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, 53-60.	0.4	49
46	Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 183-198.	0.9	62
47	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
48	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 11-18.	1.0	0
49	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1030-1045.	1.8	19
50	Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 656-670.	1.3	25
51	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	1.0	54
52	Marine-derived n-3 fatty acids therapy for stroke. <i>The Cochrane Library</i> , 2020, 2020, CD012815.	1.5	8
53	Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 107-120.	0.9	10
54	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 279-289.	2.2	33
55	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. <i>Circulation Research</i> , 2020, 126, 112-128.	2.0	45

#	ARTICLE	IF	CITATIONS
56	Clinical review on triglycerides. <i>European Heart Journal</i> , 2020, 41, 99-109c.	1.0	286
57	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100086.	1.3	10
58	Management of hypertriglyceridemia. <i>BMJ, The</i> , 2020, 371, m3109.	3.0	89
59	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020, 22, 74.	2.0	9
60	Pharmacokinetics of Single and Multiple Doses of Omega-3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open-Label Study. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 985-994.	0.8	3
61	When to lower triglycerides?. <i>Current Opinion in Lipidology</i> , 2020, 31, 238-245.	1.2	9
62	Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 45.	2.0	19
63	VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2725-2735.	1.2	105
64	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2268.	3.8	540
65	Icosapent Ethyl: Niche Drug or for the Masses?. <i>Current Cardiology Reports</i> , 2020, 22, 104.	1.3	8
66	The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. <i>Current Diabetes Reports</i> , 2020, 20, 65.	1.7	18
67	Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 139-146.	0.3	6
68	Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord. <i>Annual Review of Nutrition</i> , 2020, 40, 161-187.	4.3	23
69	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 67.	2.0	15
70	Effects of Epeleuton, a Novel Synthetic Second-Generation -3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. <i>Journal of the American Heart Association</i> , 2020, 9, e016334.	1.6	17
71	The return of triglycerides and revival of omega-3 fatty acids!. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 369-373.	0.7	6
72	Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. <i>Lipids in Health and Disease</i> , 2020, 19, 117.	1.2	3
73	Causes and Consequences of Hypertriglyceridemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 252.	1.5	122

#	ARTICLE	IF	CITATIONS
74	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 25.	2.0	38
75	Temporal decline in non-HDL high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2020, 14, 425-430.	0.6	3
76	Omega-3 fatty acid therapy for cardiovascular disease: justified or not?. <i>Current Opinion in Cardiology</i> , 2020, 35, 417-422.	0.8	3
77	Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 355-361.	0.6	25
78	Contribution of remnant cholesterol to cardiovascular risk. <i>Journal of Internal Medicine</i> , 2020, 288, 116-127.	2.7	94
79	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. <i>Future Cardiology</i> , 2020, 16, 343-350.	0.5	0
80	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1135-1147.	1.1	240
81	Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 175-180.	0.6	8
82	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 371-385.	1.5	9
83	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105060.	3.1	30
84	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103.	1.2	42
85	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	2.7	22
86	<p>Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date</p>. <i>Vascular Health and Risk Management</i> , 2020, Volume 16, 1-10.	1.0	10
87	The Rise and Fall of the HDL Hypothesis. <i>Drugs</i> , 2020, 80, 353-362.	4.9	7
88	Inflammation and cardiovascular disease: are marine phospholipids the answer?. <i>Food and Function</i> , 2020, 11, 2861-2885.	2.1	65
89	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. <i>Journal of Women's Health</i> , 2020, 29, 1091-1100.	1.5	9
90	High levels of eicosapentaenoic acid are associated with lower pericoronary adipose tissue attenuation as measured by coronary CTA. <i>Atherosclerosis</i> , 2021, 316, 73-78.	0.4	13
91	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46

#	ARTICLE	IF	CITATIONS
92	Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes. <i>Atherosclerosis</i> , 2021, 316, 58-65.	0.4	26
93	Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 79-93.	1.3	21
94	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. <i>Postgraduate Medicine</i> , 2021, 133, 28-41.	0.9	10
95	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	0.5	14
96	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
97	The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. <i>Journal of Lipids</i> , 2021, 2021, 1-5.	1.9	1
98	Impact of Dyslipidemia on Ischemic Stroke. <i>Stroke Revisited</i> , 2021, , 23-41.	0.2	0
99	Effects of Omega-3 Polyunsaturated Fatty Acids and Their Metabolites on Haemostasis—Current Perspectives in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2394.	1.8	29
100	The Truth About Fish (Oil) in the Treatment of Dyslipidemia. <i>Current Atherosclerosis Reports</i> , 2021, 23, 10.	2.0	3
101	Omega-3FAs Can Inhibit the Inflammation and Insulin Resistance of Adipose Tissue Caused by HHcy Induced Lipids Profile Changing in Mice. <i>Frontiers in Physiology</i> , 2021, 12, 628122.	1.3	2
102	Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. <i>Current Atherosclerosis Reports</i> , 2021, 23, 27.	2.0	4
103	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100149.	1.3	87
104	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , 2021, 10, e017401.	1.6	18
105	Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. <i>Journal of the American Heart Association</i> , 2021, 10, e016947.	1.6	49
106	Application of marine natural products in drug research. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 35, 116058.	1.4	63
107	Umbrella Review on Non-Statins Lipid-Lowering Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110029.	1.0	11
108	Cardiovascular effects of omega-3 fatty acids: Hope or hype?. <i>Atherosclerosis</i> , 2021, 322, 15-23.	0.4	19
109	Dietary Reference Intakes based on chronic disease endpoints: outcomes from a case study workshop for omega-3 fatty acids EPA and DHA. <i>Applied Physiology, Nutrition and Metabolism</i> , 2021, 46, 530-539.	0.9	6

#	ARTICLE	IF	CITATIONS
110	Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). <i>American Heart Journal</i> , 2021, 235, 54-64.	1.2	11
111	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 815-834.	0.6	11
112	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105776.	1.9	7
113	A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. <i>European Heart Journal</i> , 2021, 42, 4807-4817.	1.0	56
114	Association Between Achieved ω -3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2021, 6, 910.	3.0	52
115	Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers. <i>Frontiers in Pharmacology</i> , 2021, 12, 681455.	1.6	2
116	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 960-993.	1.2	146
117	Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 31-42.	1.0	7
118	Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States. <i>Contemporary Cardiology</i> , 2021, , 307-322.	0.0	3
119	Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 915-930.	5.5	97
120	The fish-oil paradox. <i>Current Opinion in Lipidology</i> , 2020, 31, 356-361.	1.2	5
121	Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 171.	0.5	39
122	Emerging Strategies for the Management of Atherogenic Dyslipidaemia. <i>European Cardiology Review</i> , 2020, 15, 1-3.	0.7	6
123	The Diagnosis and Treatment of Hypertriglyceridemia. <i>Deutsches Arzteblatt International</i> , 2019, 116, 825-832.	0.6	50
124	Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor. <i>Global Cardiology Science & Practice</i> , 2021, 2021, e202119.	0.3	2
125	6. Update for the Management of Dyslipidemia. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 146b-146b.	0.0	0
126	6. Update for the Management of Dyslipidemia. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1896-1901.	0.0	0
127	Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110534.	0.5	1

#	ARTICLE	IF	CITATIONS
128	Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). Contemporary Cardiology, 2021, , 295-306.	0.0	1
129	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology, 2021, , 139-158.	0.0	2
130	The Vitamin D and Omega-3 Trial (VITAL): Do Results Differ by Sex or Race/Ethnicity?. American Journal of Lifestyle Medicine, 2021, 15, 155982762097203.	0.8	14
131	Current and future trends in the treatment of dyslipidemias. Vnitri Lekarstvi, 2019, 65, 643-650.	0.1	2
132	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0
133	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. Nutrients, 2021, 13, .	1.7	1
134	Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery, 2021, 1, 70-104.	0.6	13
135	Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology – A Serial Computed Tomography Angiography Study. Circulation Journal, 2022, 86, 831-842.	0.7	7
136	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. Nutrients, 2021, 13, 2957.	1.7	9
137	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis, 2022, 343, 28-50.	0.4	12
138	Fatty acids. , 2022, , 257-286.		1
139	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nature Reviews Cardiology, 2022, 19, 577-592.	6.1	59
140	Ten things to know about ten cardiovascular disease risk factors – 2022. American Journal of Preventive Cardiology, 2022, 10, 100342.	1.3	34
141	Highly Efficient Electrocarboxylation Method to Synthesize Novel Acid Derivatives of 1,4-Dihydropyridines and to Study Their Antimicrobial Activity. ACS Omega, 2022, 7, 16055-16062.	1.6	9
143	Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	16
144	Marine-derived n-3 fatty acids therapy for stroke. The Cochrane Library, 2022, 2022, .	1.5	0
145	Adenosine-rich extract of Ganoderma lucidum: A safe and effective lipid-lowering substance. IScience, 2022, 25, 105214.	1.9	3
146	Chylomicronemia through a burr hole: A case report. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1

#	ARTICLE	IF	CITATIONS
147	Icosapent Ethyl for the Prevention of Cardiovascular Events. <i>EMJ Cardiology</i> , 0, , 56-65.	0.0	0
148	Comparison of the dietary omega-3 fatty acids impact on murine psoriasis-like skin inflammation and associated lipid dysfunction. <i>Journal of Nutritional Biochemistry</i> , 2023, 117, 109348.	1.9	7
149	Diabetes and Dyslipidemia. <i>Contemporary Cardiology</i> , 2023, , 425-472.	0.0	3